Related Experiment Videos
Gemfibrozil in hyperlipidaemia: an open, single blind trial
P K Varthakavi1, D P Turakhia, S S Sharma
1Department of Cardiology, T.N. Medical College, Bombay.
Insights
Gemfibrozil effectively lowers lipid levels in patients with hyperlipidemia, significantly reducing cholesterol and triglycerides while increasing HDL cholesterol. Further long-term studies are needed for optimal dosage and safety in Indian populations.
Area of Science:
- Cardiology
- Pharmacology
- Metabolic Disorders
Background:
- Hyperlipidemia, characterized by elevated blood lipid levels, is a significant risk factor for cardiovascular disease.
- Type IIA, IIB, and IV hyperlipidemia are common dyslipidemias requiring effective management.
- Gemfibrozil is a lipid-regulating agent used in managing dyslipidemias.
Purpose of the Study:
- To evaluate the efficacy of Gemfibrozil in improving lipid profiles of middle-aged subjects with hyperlipidemia.
- To assess the safety and tolerability of Gemfibrozil at a dosage of 1200 mg/day.
Main Methods:
- A study involving 36 middle-aged subjects diagnosed with type IIA, IIB, or IV hyperlipidemia.
- Administration of Gemfibrozil at a daily dose of 1200 mg for 24 weeks.
- Monitoring of lipid parameters including total cholesterol, triglycerides, VLDL, LDL, HDL, apolipoprotein A, and apolipoprotein B.
Main Results:
- Gemfibrozil demonstrated significant reductions in total cholesterol (39.91%), total triglycerides (71.10%), VLDL triglycerides (62.97%), LDL cholesterol (45.57%), and apolipoprotein B (26.83%) at 24 weeks.
- Concurrently, HDL cholesterol increased by 26.23% and apolipoprotein A levels rose by 53.67%.
- The medication was well-tolerated, with no dropouts attributed to its use.
Conclusions:
- Gemfibrozil is an effective agent for lowering adverse lipid levels in patients with hyperlipidemia.
- The drug exhibited a favorable safety profile at the studied dosage.
- Further long-term research is recommended to establish optimal dosage and long-term safety in Indian subjects.
Abstract:
The efficacy of Gemfibrozil on S. lipid levels was studied in 36 middle aged subjects with type IIA, IIB, IV hyperlipidemia. Gemfibrozil was well tolerated in the dose of 1200 mg/day and no dropouts were attributable to its use. An overall reduction in total cholesterol (39.91%), total triglycerides (71.10%), VLDL triglycerides (62.97%). LDL cholesterol (45.57%) and apolipoprotein B levels (26.83%) were observed at 24 weeks. At the same time HDL cholesterol, and apolipoprotein A levels showed increases by 26.23% and 53.67% respectively. It is concluded that Gemfibrozil is an effective lipid lowering agent. Further long term studies are necessary to determine its optimal dosage and its long term safety in Indian subjects.